LOGIN  |  REGISTER
Astria Therapeutics
Compass Therapeutics

Aimia Declares Preferred Share Dividends

March 16, 2023 | Last Trade: US$0.20 0.01 -6.89

TORONTO, March 16, 2023 /CNW/ - Aimia (TSX: AIM) announced today that the Board of Directors has declared quarterly dividends on each series of its preferred shares:

  • a quarterly dividend in the amount of $0.300125 per Cumulative Rate Reset Preferred Share, Series 1
  • a quarterly dividend of $0.375688 per Cumulative Rate Reset Preferred Share, Series 3

In each case, dividends are payable on March 31, 2023, to the holders of record at the close of business on March 24, 2023.

Dividends paid by Aimia to Canadian residents on its preferred shares are "eligible dividends" for the purpose of the Income Tax Act (Canada) and any similar applicable provincial legislation.

About Aimia

Aimia Inc. (TSX: AIM) is a holding company with a focus on making long-term investments in public and private companies, on a global basis, through controlling or minority stakes.

The company owns a portfolio of investments which include: a 10.85% stake in Clear Media Limited, one of the largest outdoor advertising firms in China, a 48.8% equity stake in Kognitiv, a B2B company enabling global brands to redefine loyalty with solutions for multi-enterprise collaboration, a 11.8% equity stake in TRADE X, a global B2B cross-border automotive trading platform as well as a wholly owned investment advisory business, Mittleman Investment Management, LLC.

For more information about Aimia, visit www.aimia.com.

Astria Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB